TrialAIDS research and human retroviruses2022

A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Ian M McGowan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.